GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2894512 1% CreamDrug: GSK2894512 0.5% CreamDrug: Vehicle cream
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 227
- Registration Number
- NCT02564042
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02563899
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Phase 2
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: GSK2894512 0.5% CreamDrug: Vehicle creamDrug: GSK2894512 1% Cream
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 247
- Registration Number
- NCT02564055
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT02563496
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
DUAC® Early Onset Efficacy Study in Japanese Subjects
Phase 4
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT02557399
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: Mepolizumab 100mgDrug: Placebo
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 306
- Registration Number
- NCT02555371
- Locations
- 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine
A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children
Not Applicable
Withdrawn
- Conditions
- Growth and Development
- Interventions
- Dietary Supplement: ControlDietary Supplement: Test Product
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02551627
Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
Phase 1
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: [11C]-GSK2256098 500 MBq
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT02551653
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: Lipopolysaccharide challengeProcedure: Saline challengeProcedure: Labelled neutrophils and Imaging assessment
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT02551614
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2981278 0.03%Drug: GSK2981278 0.1%Drug: GSK2981278 0.8%Drug: GSK2981278 4%Drug: Vehicle
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT02548052
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
© Copyright 2025. All Rights Reserved by MedPath